Pharmacokinetics of tetrahydroaminoacridine: relations to clinical and biochemical effects in Alzheimer patients.
The pharmacokinetics of tetrahydroaminoacridine (THA) was studied in patients suffering from Alzheimer's dementia. Single doses of the drug were administered by intravenous (15 mg), oral (50 mg) and rectal routes (25 mg). Pharmacokinetic parameters were related to clinical and biochemical effects in patients who, in a separate study, participated in a clinical trial of oral THA. The bioavailability of THA was low and varied considerably between subjects. Clinical improvement and occurrence of elevated liver enzymes correlated positively with drug bioavailability. Acetyl and butyryl cholinesterase activities in the plasma did not change following THA administration. Rectally administered THA had a higher bioavailability than orally administered THA in three subjects who were given the drug by both routes. These results indicate that a clinical trial of rectal THA would be justified as this administration route may improve resorption and diminish first-pass metabolism of the drug in the liver compared with oral administration.
Ahlin
A
A
Department of Psychiatry and Psychology, Karolinska Hospital, Stockholm, Sweden.
Adem
A
A
Junthé
T
T
Ohman
G
G
Nybäck
H
H
D000284:Administration, Oral; D000285:Administration, Rectal; D000368:Aged; D000544:Alzheimer Disease / Q000188:drug therapy* / Q000378:metabolism; D001682:Biological Availability; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008099:Liver / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D013619:Tacrine / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*
D013619:Tacrine